Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Mus musculus | nitric oxide synthase 2, inducible | Starlite/ChEMBL | References |
Bos taurus | Nitric-oxide synthase, endothelial | Starlite/ChEMBL | References |
Rattus norvegicus | Nitric-oxide synthase, brain | Starlite/ChEMBL | References |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Schistosoma mansoni | NADPH flavin oxidoreductase | 0.0046 | 0.0151 | 0.0151 |
Brugia malayi | FAD binding domain containing protein | 0.0091 | 1 | 1 |
Plasmodium vivax | NADPH-cytochrome p450 reductase, putative | 0.0091 | 1 | 1 |
Trypanosoma brucei | NADPH--cytochrome P450 reductase, putative | 0.0091 | 1 | 0.5 |
Mycobacterium ulcerans | formate dehydrogenase H FdhF | 0.0091 | 1 | 0.5 |
Loa Loa (eye worm) | FAD binding domain-containing protein | 0.0091 | 1 | 1 |
Trypanosoma cruzi | cytochrome P450 reductase, putative | 0.0091 | 1 | 0.5 |
Trypanosoma cruzi | NADPH-dependent FMN/FAD containing oxidoreductase, putative | 0.0091 | 1 | 0.5 |
Trypanosoma brucei | NADPH--cytochrome P450 reductase, putative | 0.0091 | 1 | 0.5 |
Schistosoma mansoni | 5-methyl tetrahydrofolate-homocysteine methyltransferase reductase | 0.0056 | 0.2407 | 0.2407 |
Echinococcus multilocularis | NADPH dependent diflavin oxidoreductase 1 | 0.0091 | 1 | 1 |
Leishmania major | NADPH-cytochrome p450 reductase-like protein | 0.0091 | 1 | 1 |
Trypanosoma cruzi | cytochrome P450 reductase, putative | 0.0091 | 1 | 0.5 |
Trichomonas vaginalis | sulfite reductase, putative | 0.0091 | 1 | 1 |
Echinococcus granulosus | NADPH dependent diflavin oxidoreductase 1 | 0.0091 | 1 | 1 |
Echinococcus granulosus | NADPH cytochrome P450 reductase | 0.0091 | 1 | 1 |
Echinococcus multilocularis | NADPH cytochrome P450 reductase | 0.0091 | 1 | 1 |
Leishmania major | p450 reductase, putative | 0.0091 | 1 | 1 |
Plasmodium falciparum | nitric oxide synthase, putative | 0.0091 | 1 | 0.5 |
Toxoplasma gondii | flavodoxin domain-containing protein | 0.0045 | 0 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0091 | 1 | 1 |
Giardia lamblia | Nitric oxide synthase, inducible | 0.0081 | 0.7743 | 0.5 |
Trypanosoma brucei | NADPH-dependent diflavin oxidoreductase 1 | 0.0091 | 1 | 0.5 |
Trypanosoma cruzi | p450 reductase, putative | 0.0091 | 1 | 0.5 |
Chlamydia trachomatis | sulfite reductase | 0.0056 | 0.2407 | 0.5 |
Toxoplasma gondii | flavodoxin domain-containing protein | 0.0045 | 0 | 0.5 |
Schistosoma mansoni | cytochrome P450 reductase | 0.0091 | 1 | 1 |
Giardia lamblia | Hypothetical protein | 0.0081 | 0.7743 | 0.5 |
Trypanosoma brucei | NADPH-cytochrome p450 reductase, putative | 0.0091 | 1 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Ki (binding) | = 1.8 nM | Compound was tested for binding affinity against recombinant inducible nitric oxide synthase (iNOS) from mouse | ChEMBL. | 9397167 |
Ki (binding) | = 1.8 nM | Compound was tested for binding affinity against recombinant inducible nitric oxide synthase (iNOS) from mouse | ChEMBL. | 9397167 |
Ki (binding) | = 57 nM | Compound was tested for binding affinity against neuronal nitric oxide synthase(nNOS) | ChEMBL. | 9397167 |
Ki (binding) | = 57 nM | Compound was tested for binding affinity against neuronal nitric oxide synthase(nNOS) | ChEMBL. | 9397167 |
Ki (binding) | = 8500 nM | Compound was tested for binding affinity against Endothelial nitric oxide synthase | ChEMBL. | 9397167 |
Ki (binding) | = 8500 nM | Compound was tested for binding affinity against Endothelial nitric oxide synthase | ChEMBL. | 9397167 |
Selectivity ratio (binding) | = 149 | Selectivity ratio for nNOS/eNOS (ratio of the inverse of the Ki values ) was determined | ChEMBL. | 9397167 |
Selectivity ratio (binding) | = 3158 | Selectivity ratio for nNOS/iNOS (ratio of the inverse of the Ki values ) was determined | ChEMBL. | 9397167 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.